The ICC has recognized RUNX1 mutations as myelodysplasia-related in AML, and therefore, cases of myeloid neoplasms with ≥10–19% blasts in the bone marrow are defined as MDS/AML, while cases with ≥20% blasts are defined as AML with myelodysplasia-related gene mutations (RUNX1). Here, RUNX1 is linked to Myelodysplasia.